Haleh Haerian, MD
Endocrinology, Diabetes & Metabolism · Altoona, PANPI 1427141407
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in PA, where the typical reported total is $1,080.
Across 2 payments — averaging $73.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BETA Bionics, Inc.$77
- Medtronic$70
What the payments were for
- Food & beverage$147100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BETA Bionics, Inc. | 1 | $77 |
| Medtronic | 1 | $70 |
How this compares
$147 in reported general payments places this provider in the 20th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 762 | $1,087,547 |
| TepezzaTeprotumumab-Trbw | 22 | $1,045,359 |
| JardianceEmpagliflozin | 443 | $542,899 |
| MounjaroTirzepatide | 321 | $450,704 |
| Teriparatide | 105 | $264,070 |
| TymlosAbaloparatide | 55 | $209,043 |
| ProliaDenosumab | 88 | $146,222 |
| FarxigaDapagliflozin Propanediol | 128 | $143,652 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 45 | $135,263 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 764 | $121,271 |
| TrulicityDulaglutide | 88 | $120,667 |
| Tresiba Flextouch U-100Insulin Degludec | 169 | $112,624 |
| Humalog Kwikpen U-100Insulin Lispro | 310 | $101,517 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $92,604 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 49 | $70,956 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Altoona
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.